Hormones and Agents Affecting Hormonal Mechanism: Estrogens, Progestins, Contraceptives and Related Agents
IPROG9 “Progeston Depot injection” 125mg/ml; 1 ml/amp
適應症：月經困難、子宮出血、習慣性流產、迫切性流
Usual dose:
Amenorrhea :
(One-time dosage) 375 mg IM
(Cyclic therapy, 28-day cycle) Estradiol valerate 20 mg IM on day 1 followed by hydroxyprogesterone caproate 250 mg IM with estradiol valerate 5 mg IM 2 weeks later. Repeat cycle every 4 weeks until cyclic therapy no longer required. May begin at any time for patients not on estrogen therapy otherwise start after 4 days of desquamation or, if no bleeding, begin 21 days after hydroxyprogesterone caproate injection alone.
Preterm labor, Singleton pregnancy; Prophylaxis:
250 mg IM once weekly (every 7 days) starting between 16 weeks, 0 days and 20 weeks, 6 days of gestation; continue until week 37 (through 36 weeks, 6 days) of gestation or delivery.
Endometrial disorder, Secretary endometrium, production and desquamation:
(Currently on estrogen therapy; one-time dosage, ) 375 mg IM; may be initiated at any time.
(Cyclic therapy, 28-day cycle) Estradiol valerate 20 mg IM on day 1 followed by hydroxyprogesterone caproate 250 mg IM with estradiol valerate 5 mg IM 2 weeks later. Repeat cycle every 4 weeks until cyclic therapy no longer required. May begin at any time for patients not on estrogen therapy otherwise start after 4 days of desquamation or, if no bleeding, begin 21 days after hydroxyprogesterone caproate injection alone.
Contraindication: Current or history of thrombosis or thromboembolic disorders；breast cancer or other hormone-sensitive cancer (known, suspected, or history of)； undiagnosed abnormal vaginal bleeding unrelated to pregnancy; cholestatic jaundice of pregnancy；liver tumors (benign or malignant) or active liver disease；uncontrolled hypertension.
Precaution: allergic reactions, including angioedema；arterial or deep venous thrombotic or thromboembolic events may occur；decreased glucose tolerance may occur (including prediabetic women)；fluid retention ,hypertension, jaundice may occur
Adverse effect:
Common: injection site pain, injection site pruritus, injection site reaction, pruritus, swelling at injection site, urticaria, diarrhea, nausea.
Serious: thromboembolic disorder